Abbreviations used:AE ( adverse event), CR ( complete response), DOCB ( duration of clinical benefit), DOR ( duration of response), MF ( mycosis fungoides), mSWAT ( modified severity weighted assessment tool), ORR ( overall response rate), PD ( progressive disease), PR ( partial response), TSEBT ( total skin electron beam therapy), TTP ( time to progression), TTR ( time to response)
- World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues.4th ed. IARC Press, Lyon2008
- Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.Arch Dermatol. 2007; 143: 854-859
- Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC).Blood. 2007; 110: 1713-1722
- AJCC cancer staging manual.Springer, New York2010
National Comprehensive Cancer Network. Non-Hodgkin's lymphoma (Version 4.2014). http://www.nccn.org/about/nhl.pdf. Accessed November 4, 2014.
- Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression.Arch Dermatol. 2003; 139: 857-866
- Electron beam treatment for cutaneous T-cell lymphoma.Hematol Oncol Clin North Am. 1995; 9: 1057-1076
- Dose considerations in total skin electron radiation in mycosis fungoides.Am J Roentgenol. 1979; 132: 261-263
- Mycosis fungoides: radiation therapy.Dermatol Ther. 2003; 16: 347-354
- Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides.Int J Radiat Oncol Biol Phys. 1995; 32: 1445-1449
- Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma.J Am Acad Dermatol. 1996; 35: 69-73
- Revisiting low dose total skin electron beam therapy in mycosis fungoides.Int J Radiat Oncol Biol Phys. 2011; 81: e651-e657
- Radiation therapy in the management of cutaneous T-cell lymphoma.Cancer Treat Rep. 1979; 63: 625-632
- Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer.J Clin Oncol. 2011; 29: 2598-2607
- Topical corticosteroids for mycosis fungoides: experience in 79 patients.Arch Dermatol. 1998; 134: 949-954
- Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience.Arch Dermatol. 2003; 139: 165-173
- Narrowband UVB phototherapy for early-stage mycosis fungoides.J Am Acad Dermatol. 2002; 47: 191-197
- Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.Arch Dermatol. 2001; 137: 581-593
- Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.J Clin Oncol. 2007; 25: 3109-3115
- Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study.Br J Dermatol. 2011; 166: 399-404
This study was partially supported by the Haas Family Foundation and Merck .
Conflicts of interest: None declared.